Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database

被引:29
|
作者
Shu, Yamin [1 ]
Zhang, Qilin [2 ]
He, Xucheng [3 ]
Liu, Yanxin [4 ]
Wu, Pan [5 ]
Chen, Li [6 ,7 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Pharm, Tongji Med Coll, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Dept Pharm, Tongji Med Coll, Wuhan, Peoples R China
[3] Pengzhou Second Peoples Hosp, Dept Pharm, Pengzhou, Peoples R China
[4] Pengzhou Peoples Hosp, Dept Pharm, Pengzhou, Peoples R China
[5] Chengfei Hosp, Dept Pharm, Chengdu, Peoples R China
[6] Sichuan Univ, West China Univ Hosp 2, Dept Pharm, Chengdu, Peoples R China
[7] Sichuan Univ, West China Univ Hosp 2, Evidence Based Pharm Ctr, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
data mining; FAERS; fluoroquinolones; pharmacovigilance; tendonitis; tendon rupture; RISK; LEVOFLOXACIN; TENDINOPATHY; CIPROFLOXACIN; MOXIFLOXACIN;
D O I
10.3389/fphar.2022.990241
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The objective of this study was to scientifically and systematically explore the association between fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) and tendonitis and tendon rupture through the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: Disproportionality analysis was used to quantify the signals of fluoroquinolone-associated suspected tendonitis and tendon rupture based on the FAERS data from January 2016 to March 2021. Clinical characteristics, the onset time, oral and intravenous administrations, and the serious outcomes of fluoroquinolone-associated tendonitis and tendon rupture were further analyzed. Results: Out of 35,667 fluoroquinolone-associated adverse events recorded in the FAERS database during the study period, 1,771 tendonitis and 1,018 tendon ruptures induced by fluoroquinolones as the suspected drug were analyzed, with a median age of 49.88-63.87 years. All three fluoroquinolones detected positive signals of tendonitis and tendon rupture in the four methods. Ciprofloxacin had the strongest statistical association with tendonitis with the highest positive signal values (ROR 98.50, PRR 93.25, IC 6.15, and EBGM 76.80), while levofloxacin showed the strongest statistical association with tendon rupture (ROR 76.38, PRR 73.75, IC 5.84, and EBGM 63.89). Compared with ciprofloxacin and levofloxacin, moxifloxacin was relatively weakly associated with tendonitis and tendon rupture. Oral fluoroquinolone-induced tendonitis and tendon rupture had a stronger signal strength than intravenous administration. The majority of fluroquinolone-related suspected tendonitis and tendon rupture tended to occur within a few days or one month. As for the disability rate of tendonitis, ciprofloxacin counted the highest (n = 461, 50.94%), with moxifloxacin the lowest (n = 20, 29.41%). Conclusion: Fluoroquinolone-induced tendonitis and tendon rupture tended to occur early and might result in serious outcomes. Our study provided valuable references for early identification of the risk of fluoroquinolone-induced tendonitis and tendon rupture.
引用
收藏
页数:10
相关论文
共 9 条
  • [1] Anti-seizure medications-associated bladder and urethral symptoms: a pharmacovigilance analysis based on the FAERS database
    Li, Yanyan
    Wu, Zhanshen
    Zhao, Yang
    Shi, Lei
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [2] Severe cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database
    Shan, Huifang
    Wei, Chunyan
    Zhang, Jingyi
    Wu, Bin
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [3] Reproductive Toxicity Induced by Serotonin-Norepinephrine Reuptake Inhibitors: A Pharmacovigilance Analysis From 2004 to 2023 Based on the FAERS Database
    Xi, Yujia
    Bao, Zhuocheng
    Guo, Qiang
    Wang, Jingqi
    Jing, Zhinan
    Di, Jingkai
    Yang, Ke
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (12)
  • [4] Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials
    Chen, Wei
    Xie, Jiyi
    Gao, Chen
    Zhang, Cong
    Fu, Zhiwen
    Shi, Chen
    GYNECOLOGIC ONCOLOGY, 2024, 182 : 108 - 114
  • [5] Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database
    Konstantinov, Konstantin
    Dolladille, Charles
    Gillet, Benjamin
    Alexandre, Joachim
    Aouba, Achille
    Deshayes, Samuel
    Repesse, Yohann
    HAEMOPHILIA, 2023, 29 (01) : 186 - 192
  • [6] Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
    Li, Zhaohui
    Zhou, Zixiang
    Zhang, Nan
    Tian, Binhe
    Chen, Xiangqi
    Zhao, Haitao
    Wang, Hanping
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 74 (01)
  • [7] Cyclin-dependent kinase 4/6 inhibitor-associated pulmonary toxicity: a disproportionality analysis from 2015 to 2023 based on the FAERS database
    Cheng, Qian
    Qi, Junsheng
    Zou, Shupeng
    Shi, Xuan
    Zhao, Yazheng
    Ouyang, Mengling
    Sun, Minghui
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [8] Adverse Drug Reactions Relevant to Drug Resistance and Ineffectiveness Associated with Meropenem, Linezolid, and Colistin: An Analysis Based on Spontaneous Reports from the European Pharmacovigilance Database
    Vintila, Bogdan Ioan
    Arseniu, Anca Maria
    Butuca, Anca
    Sava, Mihai
    Birlutiu, Victoria
    Rus, Luca Liviu
    Axente, Dan Damian
    Morgovan, Claudiu
    Gligor, Felicia Gabriela
    ANTIBIOTICS-BASEL, 2023, 12 (05):
  • [9] A Pharmacovigilance Study Regarding the Risk of Antibiotic-Associated Clostridioides difficile Infection Based on Reports from the EudraVigilance Database: Analysis of Some of the Most Used Antibiotics in Intensive Care Units
    Vintila, Bogdan Ioan
    Arseniu, Anca Maria
    Morgovan, Claudiu
    Butuca, Anca
    Sava, Mihai
    Birlutiu, Victoria
    Rus, Luca Liviu
    Ghibu, Steliana
    Bereanu, Alina Simona
    Codru, Ioana Roxana
    Gligor, Felicia Gabriela
    PHARMACEUTICALS, 2023, 16 (11)